Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  European Journal of Pharmacology

• Publication date

  1997-03-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0014-2999(96)00966-1PMID 9085051
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of human neuroblastoma growth by a specific VIP antagonist

  2007cited by this paper
• Functional and molecular characterization of VIP receptors and signal transduction in human and rodent immune systems.

  1996cited by this paper
• Characterization of adenylyl cyclase stimulated by VIP in rat and mouse peritoneal macrophage membranes.

  1996cited by this paper
• VIP modulation of immune cell functions.

  1996cited by this paper
• Growth hormone is a human macrophage activating factor. Priming of human monocytes for enhanced release of H2O2.

  1995cited by this paper
• Vasoactive intestinal peptide and substance P receptor antagonists improve postoperative ileus.

  1995cited by this paper
• Vasoactive intestinal polypeptide antagonists attenuate vagally induced tachycardia in the anesthetized dog.

  1995cited by this paper
• A new vasoactive intestinal peptide antagonist discriminates VIP receptors on guinea pig trachea and human neuroblastoma cells.

  1994cited by this paper
• Expression of VIP receptors in mouse peritoneal macrophages: functional and molecular characterization.

  1994cited by this paper
• A chimeric VIP-PACAP analogue but not VIP pseudopeptides function as VIP receptor antagonists.

  1994cited by this paper
• Characteristics of receptors for VIP in rat peritoneal macrophage membranes.

  1994cited by this paper
• Vasoactive intestinal peptide (VIP) inhibits substrate adherence capacity of rat peritoneal macrophages by a mechanism that involves cAMP.

  1993cited by this paper
• Role of sulfhydryl groups in the binding of vasoactive intestinal peptide to its receptor on murine lymphocytes.

  1992cited by this paper
• Stimulatory effect of vasoactive intestinal peptide (VIP) on cyclic AMP production in rat peritoneal macrophages.

  1992cited by this paper
• Guanine nucleotide regulation of VIP binding to rat peritoneal macrophage membranes.

  1992cited by this paper
• Modulation of human natural killer activity by vasoactive intestinal peptide (VIP) family. VIP, glucagon and GHRF specifically inhibit NK activity.

  1992cited by this paper
• Vasoactive Intestinal Peptide and Immune Function

  1991cited by this paper
• Vasoactive intestinal polypeptide: biologic role in health and disease.

  1991cited by this paper
• Characterization of functional receptors for vasoactive intestinal peptide (VIP) in rat peritoneal macrophages.

  1991cited by this paper
• Vasoactive intestinal peptide receptor antagonists in rat seminal vesicle membranes.

  1991cited by this paper
• An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system.

  1991cited by this paper
• An analogue of growth hormone releasing factor (GRF), (Ac-Try1, D-Phe2)-GRF-(1-29), specifically antagonizes the facilitation of the flexor reflex induced by intrathecal vasoactive intestinal peptide in rat spinal cord.

  1991cited by this paper
• Vasoactive intestinal peptide (VIP) as transmitter of inhibitory motor neurons of the gut: evidence from the use of selective VIP antagonists and VIP antiserum.

  1990cited by this paper
• VIP antagonist [N-Ac-Tyr1,D-Phe2]-GRF-(1-29)-NH2: an inhibitor of vasodilation in the feline colon.

  1990cited by this paper
• High affinity specific binding of vasoactive intestinal peptide to human circulating T cells, B cells and large granular lymphocytes.

  1990cited by this paper
• Secretory actions of vasoactive intestinal polypeptide, peptide histidine isoleucine and helodermin in rat small intestine: the effects of putative VIP antagonists upon VIP-induced ion secretion.

  1989cited by this paper
• Vasoactive intestinal peptide stimulation of renal adenylate cyclase and antagonism by (4Cl-d-Phe6Leu17)VIP

  1989cited by this paper
• Vasoactive Intestinal Peptide Stimulation of Feline Renal Adenylate Cyclase. Inhibitory Effects of (4Cl‐d‐Phe6, Leu17)VIP a

  1988cited by this paper
• Binding of vasoactive intestinal polypeptide to dispersed enterocytes results in rapid removal of the NH2-terminal histidyl residue.

  1987cited by this paper
• Vasoactive intestinal peptide receptor antagonist [4Cl-D-Phe6, Leu17] VIP.

  1986cited by this paper
• Interaction of vasoactive intestinal peptide (VIP) with human peripheral blood lymphocytes: specific binding and cyclic AMP production.

  1986cited by this paper
• A fragment of vasoactive intestinal peptide, VIP(10-28), is an antagonist of VIP in the colon carcinoma cell line, HT29.

  1986cited by this paper
• Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.

  1986cited by this paper
• Interaction of vasoactive intestinal peptide (VIP) with rat lymphoid cells.

  1986cited by this paper
• Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT-29.

  1985cited by this paper
• Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.

  1985cited by this paper
• Binding of vasoactive intestinal polypeptide (VIP) by human blood monocytes: demonstration of specific binding sites.

  1985cited by this paper
• Receptors for vasoactive intestinal peptide and secretin on rat pancreatic acini.

  1984cited by this paper
• Effects of HIS1 modifications on the ability of vasoactive intestinal peptide to stimulate adenylate cyclase from rat and human tissues.

  1984cited by this paper
• Specific binding of vasoactive intestinal peptide to human circulating mononuclear cells.

  1983cited by this paper
• Vasoactive intestinal polypeptide modulation of lymphocyte adenylate cyclase.

  1981cited by this paper
• Interaction of vasoactive intestinal peptide with human blood mononuclear cells.

  1981cited by this paper
• Ligand: a versatile computerized approach for characterization of ligand-binding systems.

  1980cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Polypeptide with Broad Biological Activity: Isolation from Small Intestine

  1970cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• THE PHARMACOLOGICAL DIFFERENTIATION OF ADRENERGIC RECEPTORS *

  1967cited by this paper
• THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS

  1949cited by this paper

• Structural Parameters of the M33 Star Cluster System

  2013cites this paper
• The Significance of Vasoactive Intestinal Peptide in Immunomodulation

  2004influential citation
• Functional and molecular characterization of VIP receptor--effector system in rat developing immunocompetent cells: G protein involvement.

  2000cites this paper
• VIP activates G(s) and G(i3) in rat alveolar macrophages and G(s) in HEK293 cells transfected with the human VPAC(1) receptor.

  2000cites this paper
• VIP Activates Gs and Gi3 in Rat Alveolar Macrophages and Gs in HEK293 Cells Transfected with the Human VPAC1 Receptor

  2000cites this paper
• Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems

  1998cites this paper